trapidil has been researched along with Hyperparathyroidism in 2 studies
Trapidil: A coronary vasodilator agent.
Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turner, RT | 2 |
| Iwaniec, UT | 1 |
| Marley, K | 1 |
| Sibonga, JD | 2 |
| Lotinun, S | 1 |
2 other studies available for trapidil and Hyperparathyroidism
| Article | Year |
|---|---|
The role of mast cells in parathyroid bone disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Androstadienes; Animals; Benzamides; Bone Diseases, Meta | 2010 |
Triazolopyrimidine (trapidil), a platelet-derived growth factor antagonist, inhibits parathyroid bone disease in an animal model for chronic hyperparathyroidism.
Topics: Animals; Bone Diseases; Female; Hyperparathyroidism; Parathyroid Hormone; Platelet-Derived Growth Fa | 2003 |